The current state and future directions of RNAi-based therapeutics
The recent approval of the first RNA interference (RNAi)-based therapy has generated considerable excitement in the field. Here, Rossi and colleagues discuss key advances in the design and development of RNAi drugs leading up to this landmark achievement, assess the current clinical pipeline and highlight future opportunities and challenges for RNAi-based therapeutics.
Subjects Drug discovery RNAi therapy An Author Correction to this article was published on 24 April 2019 A Publisher Correction to this article was published on 18 March 2019 This article has been updated Abstract The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells. Small double-stranded RNA molecules can efficiently trigger RNAi silencing of specific genes, but their therapeutic use has faced numerous challenges involving safety and potency. However, August 2018 marked a new era for the field, with the US Food and Drug Administration approvin
Explore this link on the map →saved by
related reading
- Frontiers | Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Diseasefrontiersin.org
- Riboswitches, RNA Regulation | Learn Science at Scitablenature.com
- Targeting telomerase for cancer therapy | Oncogenenature.com
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov
- Where are all the trillion dollar biotechs?ladanuzhna.xyz
- Medicine's Endgamenotboring.co
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news
- mRNA vaccines — a new era in vaccinology | Nature Reviews Drug Discoverynature.com
- New tools for programming biology - by Elliot Hershbergcenturyofbio.com
- Checking your browser - reCAPTCHAncbi.nlm.nih.gov